Get a proposal

Respiratory · Clinical trials

Alpha-1 Antitrypsin Deficiency Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About alpha-1 antitrypsin deficiency — and why its trials are hard

Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder in which mutations (most commonly the Z allele) reduce circulating alpha-1 antitrypsin, a protease inhibitor that protects lung tissue from neutrophil elastase. Low levels lead to early-onset emphysema, particularly in smokers, while polymerised protein retained in hepatocytes can cause liver disease. Management centres on smoking cessation, standard COPD therapies, vaccination and, for liver disease, transplantation. The disease-specific therapy is intravenous augmentation therapy using pooled human plasma-derived alpha-1 proteinase inhibitor (A1-PI), which raises serum and lung antitrypsin levels above a protective threshold. Products include Prolastin, Zemaira, Aralast and Glassia. Regulatory approval was based on biochemical efficacy (achieving target serum levels) rather than hard clinical outcomes, and randomised evidence for slowing emphysema progression is limited: the RAPID trial demonstrated a significant reduction in the decline of CT-measured lung density, though effects on FEV1 and exacerbations were not clearly established. Augmentation does not treat the associated liver disease. Newer approaches, including RNA-targeted therapies for the liver phenotype, remain investigational.

Indication
Alpha-1 Antitrypsin Deficiency
ICD-10-CM
E88.01 — Alpha-1-antitrypsin deficiency

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Alpha-1 proteinase inhibitor (human), pooled A1-PI (Prolastin (also Zemaira, Aralast, Glassia))(unverified) Prolastin first approved 1987; RAPID trial published 2015Chronic augmentation/maintenance in adults with AATD and clinical emphysemaRAPID (phase 3/4, Lancet 2015) for A1-PI (Zemaira/Respreeza)Rate of decline in lung density measured by CT densitometrySignificant slowing of annual lung-density decline versus placebo; note limited RCT evidence for FEV1 or exacerbation benefit

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in alpha-1 antitrypsin deficiency development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
Inhaled alpha-1 antitrypsin (aerosolised AAT augmentation) — Randomised trials of inhaled AAT (e.g., Kamada inhaled AAT programme)Did not meet primary clinical endpoints (e.g., time to exacerbation) sufficient for approvalInsufficient lung interstitial delivery to protective levels and endpoint/powering challenges; specific trial values (unverified)

Choosing the right endpoint

Primary endpoints that matter in alpha-1 antitrypsin deficiency trials

  • Serum alpha-1 antitrypsin level (trough) — Biochemical surrogate; augmentation aims to exceed the ~11 uM (~0.57 g/L) protective threshold
  • CT lung densitometry — Sensitive measure of emphysema progression; primary endpoint in the RAPID trial
  • FEV1 decline — Traditional COPD endpoint but relatively insensitive in AATD trials
  • Exacerbation frequency — Clinically meaningful but not robustly improved in augmentation RCTs
  • Mortality / lung transplant-free survival — Long-term outcomes rarely powered in AATD studies

How iNGENū runs alpha-1 antitrypsin deficiency trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

Planning a alpha-1 antitrypsin deficiency trial?
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Request a proposal

Frequently asked questions

Alpha-1 Antitrypsin Deficiency clinical trials — FAQs

What is the disease-specific treatment for AATD lung disease?
Intravenous augmentation therapy with pooled human alpha-1 proteinase inhibitor (e.g., Prolastin, Zemaira) raises antitrypsin to protective levels. Smoking cessation is essential.
Does augmentation therapy have strong outcome evidence?
Evidence is limited. The RAPID trial showed slowed CT lung-density decline, but robust randomised data on FEV1 decline, exacerbations and mortality are lacking.
Does augmentation treat the liver disease?
No. Augmentation addresses the protease imbalance in the lung. Liver disease from retained polymerised protein is managed separately, with transplantation in severe cases.

Ready to discuss your alpha-1 antitrypsin deficiency trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal